The Idiopathic Thrombocytopenic Purpura market is poised for significant expansion through 2032, underpinned by rising disease awareness, improving epidemiological understanding, and a vibrant ...

The combination of IO or any other ADC-targeting B cells with rituximab is based on the fact that most B-cell NHLs express both CD22 and CD20; treatment with both agents provides distinct and ...

Late-onset neutropenia is emerging as a common adverse effect of rituximab when used in the treatment of autoimmune diseases. Is this late effect as widespread as it seems?

Monitoring platelet counts, managing symptoms, staying on top of treatment: Life with immune thrombocytopenia (ITP) can be stressful. Take these steps to help minimize the challenges of ITP.

STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of PROLIA ® (denosumab) and XGEVA ® (denosumab) respectively [1], [2] STOBOCLO and OSENVELT, among ...